Back

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents

OBJECTIVE 1 Formulate strategies to address the joint health-related unmet needs of patients with hemophilia in clinical practice. OBJECTIVE 2 Assess the impact of factor-based replacement therapies on FVIII levels according to the guidelines. OBJECTIVE 3 Evaluate the safety and efficacy of newly approved rebalancing agents and implement integration strategies that support personalized, patient-focused hemophilia management.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 1 credit
  • Commercial Support
  • Released
    Apr 30, 2026
  • Last day to claim credit
    May 1, 2027 7 months left